A Phase 2 clinical trial involving gonadorelin was updated on October 30, 2026. The study, titled "The COSMYC Trial (COmbined Suppression of MYC)," is registered under identifier NCT06922318. According to the listing, the trial status is currently recruiting. The trial is designated as Phase 2 on ClinicalTrials.gov. No outcome data, efficacy results, or safety findings have been reported as part of this update. The listing reflects only the trial's current recruitment status and phase classification. Gonadorelin remains an approved compound, and its inclusion in this trial does not imply any change to its existing regulatory status. Readers interested in enrollment criteria, trial design, or further details should consult the official registration page directly. This update is limited strictly to the recruiting status and phase information provided in the trial record as of the stated date. No additional claims about the trial's purpose, mechanism, or anticipated results can be made beyond what is listed in the registry entry at this time. For more background on gonadorelin, see the compound overview linked below.
Gonadorelin Featured in Phase 2 COSMYC Trial, Now Recruiting
See the full gonadorelin overview
Source: https://clinicaltrials.gov/study/NCT06922318